Allergan plc (ACT) Receiving Somewhat Positive News Coverage, Analysis Shows

News coverage about Allergan plc (NYSE:ACT) has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Allergan plc earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 46.683380899835 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern Sentiment’s analysis:

Allergan plc (ACT) opened at 299 on Friday. Allergan plc has a 12-month low of $202.00 and a 12-month high of $318.00. The company’s 50-day moving average price is $297.00 and its 200-day moving average price is $285.00.

COPYRIGHT VIOLATION WARNING: “Allergan plc (ACT) Receiving Somewhat Positive News Coverage, Analysis Shows” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at

About Allergan plc

Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business.

Insider Buying and Selling by Quarter for Allergan plc (NYSE:ACT)

Receive News & Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related companies with's FREE daily email newsletter.

Leave a Reply